Finepoint Capital LP Reduces Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Finepoint Capital LP trimmed its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 2.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 184,872 shares of the biotechnology company’s stock after selling 5,200 shares during the quarter. Ascendis Pharma A/S makes up 1.6% of Finepoint Capital LP’s holdings, making the stock its 7th largest holding. Finepoint Capital LP owned about 0.30% of Ascendis Pharma A/S worth $25,451,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Artisan Partners Limited Partnership lifted its position in shares of Ascendis Pharma A/S by 0.9% in the fourth quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company’s stock worth $612,689,000 after purchasing an additional 39,309 shares in the last quarter. American Century Companies Inc. lifted its position in Ascendis Pharma A/S by 17.5% in the 4th quarter. American Century Companies Inc. now owns 407,294 shares of the biotechnology company’s stock worth $56,072,000 after buying an additional 60,548 shares in the last quarter. Groupama Asset Managment acquired a new stake in shares of Ascendis Pharma A/S during the 3rd quarter valued at $60,000. ARS Investment Partners LLC grew its holdings in shares of Ascendis Pharma A/S by 0.9% during the 4th quarter. ARS Investment Partners LLC now owns 265,480 shares of the biotechnology company’s stock valued at $36,549,000 after acquiring an additional 2,369 shares in the last quarter. Finally, New York State Common Retirement Fund increased its stake in shares of Ascendis Pharma A/S by 14.0% in the fourth quarter. New York State Common Retirement Fund now owns 204,482 shares of the biotechnology company’s stock worth $28,151,000 after acquiring an additional 25,164 shares during the last quarter.

Ascendis Pharma A/S Price Performance

NASDAQ:ASND opened at $142.67 on Friday. The stock has a market cap of $8.66 billion, a P/E ratio of -20.09 and a beta of 0.61. The company has a fifty day moving average price of $146.39 and a 200 day moving average price of $138.01. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.64. As a group, equities research analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Analysts Set New Price Targets

ASND has been the topic of a number of recent research reports. Evercore ISI boosted their target price on Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an “outperform” rating in a research note on Tuesday, February 18th. JPMorgan Chase & Co. raised their price objective on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, March 18th. Cantor Fitzgerald increased their price target on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 25th. UBS Group started coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price objective for the company. Finally, Morgan Stanley set a $180.00 target price on shares of Ascendis Pharma A/S in a research report on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and an average price target of $204.64.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.